Sernova Biotherapeutics Inc - SEOVF STOCK NEWS

Sernova Corp. (OTCQB: SEOVF) announced advancements in its collaboration with Evotec SE, focusing on a pioneering off-the-shelf cell therapy for Type 1 Diabetes (T1D). The combination of Evotec’s iPSC-derived islet-like clusters with Sernova’s Cell Pouch aims for a 2024 regulatory filing for clinical trials. Key achievements include scalable islet cluster manufacturing and successful T1D preclinical model results, showcasing long-term insulin independence. The partnership aims to provide a potential functional cure for insulin-dependent diabetes, reducing patient reliance on daily insulin.

Sernova Corp. has announced a leadership transition, with Dr. Philip Toleikis stepping down as CEO to become Chief Technology Officer. The company is actively searching for a new CEO to guide its next growth phase, particularly as it aims to expand in US capital markets. Dr. Toleikis has led the firm for 13 years, developing its Cell Pouch System for treating chronic diseases like diabetes. The transition aims to ensure continued advancements in the company’s technology and therapies. The executive search firm Slone Partners is assisting in the recruitment process.

Sernova Corp. (OTCQB:SEOVF) announced significant advancements in its clinical trial for type 1 diabetes. With the recent implantation of the 10-channel Cell Pouch in the second cohort of its Phase 1/2 study, the company enhances capacity and aims for optimized dosing. Patient recruitment has surged due to a new strategy, and interim data is expected in 2023. This trial aims for key efficacy endpoints, potentially paving the way for a pivotal Phase 3 program. The Cell Pouch System aims to provide a functional cure for diabetes, targeting insulin independence for patients.

Sernova Corp. (OTCQB:SEOVF) announced its participation in the Stifel Healthcare Conference on November 15-16, 2022, in New York. Dr. Philip Toleikis, President & CEO, will present on November 15 at 9:45 AM. Sernova is focused on developing regenerative cell therapeutic technologies for chronic diseases, primarily through its Cell Pouch System, aimed at providing a 'functional cure' for insulin-dependent diabetes. The company is also involved in partnerships to enhance its therapies, including a strategic collaboration with Evotec for iPSC-based beta cell replacement.

Sernova Corp. has made significant progress in its Phase 1/2 clinical trial of the Cell Pouch System for type 1 diabetes, receiving approval for a protocol amendment from the University of Chicago IRB. This allows for the testing of a second cohort of patients using an enhanced 10-channel Cell Pouch, which offers 50% greater islet capacity. Interim results from the initial cohort have informed dose optimizations, and rapid enrollment is expected due to engagement with a clinical trial recruitment agency. Further results may lead to a pivotal study design for a future BLA submission to the FDA.

Sernova Corp., a leader in regenerative cell therapeutics, announced its participation at the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022, in New York City. Dr. Philip Toleikis, President & CEO, will present and engage in one-on-one investor meetings. The company focuses on developing innovative solutions for chronic diseases, aiming for a 'functional cure' for insulin-dependent diabetes through its Cell Pouch System. This system provides a safe environment for therapeutic cells, potentially serving millions of patients with diabetes and other conditions.

Sernova Corp. announced the successful exercise of all remaining share purchase warrants from a 2020 private placement, resulting in an additional $3.5 million raised. This capital will support the continued development of the Cell Pouch System for treating chronic diseases, including diabetes and hemophilia A. Dr. Philip Toleikis, President and CEO, emphasized this as a strong indicator of shareholder confidence in the company's fundamentals. Sernova now holds its strongest cash position to date, enhancing its capacity to progress in clinical studies aimed at functional cures.

Sernova Corp. (OTCQB: SEOVF) will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14, 2022, and the LifeSci Partners HealthTech Symposium on September 20-21, 2022. CEO Dr. Philip Toleikis will present at both events, with the Wainwright presentation scheduled for September 13 at 9:00 AM ET. The company aims to highlight its regenerative medicine technologies, including the Cell Pouch System for chronic diseases like diabetes. For more details, visit Sernova's investor events page.

Sernova Corp. (OTCQB:SEOVF) announced the appointment of Daniel Mahony, Ph.D. to its Board of Directors, effective September 30, 2022. Dr. Mahony, an experienced biopharma entrepreneur, has over 25 years in healthcare investment and management. He previously co-headed Healthcare at Polar Capital, managing over $4 billion in assets. His expertise spans biotechnology and healthcare services, which will be vital for Sernova's focus on regenerative medicine. Dr. Mahony replaces Dr. Dohrmann as Evotec’s representative and aims to advance Sernova’s Cell Pouch System for chronic diseases.